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Abstract
Background: Although personal cigarette smoking is the most important cause and modulator of
chronic obstructive pulmonary disease (COPD), secondhand smoke (SHS) exposure could
influence the course of the disease. Despite the importance of this question, the impact of SHS
exposure on COPD health outcomes remains unknown.
Methods: We used data from two waves of a population-based multiwave U.S. cohort study of
adults with COPD. 77 non-smoking respondents with a diagnosis of COPD completed direct SHS
monitoring based on urine cotinine and a personal badge that measures nicotine. We evaluated the
longitudinal impact of SHS exposure on validated measures of COPD severity, physical health
status, quality of life (QOL), and dyspnea measured at one year follow-up.
Results: The highest level of SHS exposure, as measured by urine cotinine, was cross-sectionally
associated with poorer COPD severity (mean score increment 4.7 pts; 95% CI 0.6 to 8.9) and
dyspnea (1.0 pts; 95% CI 0.4 to 1.7) after controlling for covariates. In longitudinal analysis, the
highest level of baseline cotinine was associated with worse COPD severity (4.7 points; 95% CI -
0.1 to 9.4; p = 0.054), disease-specific QOL (2.9 pts; -0.16 to 5.9; p = 0.063), and dyspnea (0.9 pts;
95% CI 0.2 to 1.6 pts; p < 0.05), although the confidence intervals did not always exclude the no
effect level.
Conclusion: Directly measured SHS exposure appears to adversely influence health outcomes in
COPD, independent of personal smoking. Because SHS is a modifiable risk factor, clinicians should
assess SHS exposure in their patients and counsel its avoidance. In public health terms, the effects
of SHS exposure on this vulnerable subpopulation provide a further rationale for laws prohibiting
public smoking.
Published: 06 June 2006
BMC Pulmonary Medicine 2006, 6:12 doi:10.1186/1471-2466-6-12
Received: 21 March 2006
Accepted: 06 June 2006
This article is available from: http://www.biomedcentral.com/1471-2466/6/12
© 2006 Eisner et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Pulmonary Medicine 2006, 6:12 http://www.biomedcentral.com/1471-2466/6/12
Page 2 of 11
(page number not for citation purposes)
Background
Personal direct cigarette smoking is the most important
single causal factor for developing COPD. The view that
cigarette smoking is the sole meaningful factor in the epi-
demiology and natural history of COPD, however, is a
misconception. Although direct cigarette smoking is the
major cause of COPD, up to two cases out of ten cannot
be attributable solely to this risk factor.[1] Other expo-
sures, particularly secondhand smoke (SHS) exposure and
occupational exposures, may be important in the develop-
ment of COPD.[2-4] In terms of disease progression,
other initiators of COPD besides direct smoking may also
influence the course of the disease and its eventual health
outcomes. Although SHS exposure among adults with
COPD appears to be common, the effects of SHS have not
been systematically examined in persons with established
COPD.[5,6]
Because SHS contains many potent respiratory irritants, it
is biologically plausible that exposure would adversely
affect the clinical course of established COPD. Supporting
this hypothesized causal relationship, it is known that
SHS exposure has negative effects on adults with estab-
lished asthma, including greater respiratory symptom
severity, increased asthma medication use, impaired
health-related quality of life, and more frequent hospital-
izations for asthma.[7-11] Nonetheless, the specific effects
of SHS exposure on COPD have not been elucidated.[5,6]
We used data from a population-based prospective cohort
study to examine the impact of directly measured current
SHS exposure on COPD-related health status.
Methods
Overview
We used data from a population-based prospective cohort
study of adults with COPD. SHS exposure was assessed
using both self-report from structured telephone inter-
views and direct exposure assessment (urine cotinine and
personal nicotine badge monitors). Using these exposure
and outcomes data, we examined the longitudinal associ-
ation between SHS exposure and health status among per-
sons with COPD.
Definition of COPD
We used the standard epidemiologic approach to define
COPD based on a self-reported physician diagnosis of
chronic bronchitis, emphysema, or COPD.[12-14] During
the telephone interview, subjects were asked whether they
had ever received a physician's diagnosis of any of several
chronic respiratory conditions. Those who reported phy-
sician diagnoses of chronic bronchitis or emphysema
were considered to have COPD, along with those who
specifically reported a physician diagnosis of COPD. We
included respondents with COPD who had concomitant
asthma because they clinically resemble persons with
COPD alone.[15] As reported previously, we validated the
case definition of COPD using spirometry in a subgroup
of 47 participants with COPD whose physicians provided
spirometry reports (of 386 subjects).[2]
Study recruitment
The study was approved by the University of California,
San Francisco Committee on Human Research. We used
data from wave 3 and wave 4 of a population-based multi-
wave longitudinal cohort study of U.S. adults to elucidate
the impact of SHS exposure on COPD health outcomes.
Direct measures of SHS exposure were obtained only in
these waves. Initial recruitment was previously reported in
detail.[2,4]. Briefly, 2,113 adults aged 55 to 75 years were
initially recruited by random digit dialing among resi-
dents of the 48 contiguous U.S. states with random over-
sampling of geographic areas that had the highest pub-
lished COPD mortality rates.[16] The random "hot spot"
sample was further enriched by randomly over-sampling
subjects with COPD. The initial overall study participa-
tion rate was 53% among households with an eligible
respondent present and there were 383 subjects with
COPD.
Details of the wave 2 follow-up interview have also been
previously reported.[17] Approximately 12 months after
the initial interview, we attempted to contact all 517 sub-
jects who reported either COPD or asthma at baseline
interview. Of these subjects, 352 (68%) completed the
follow-up interview, of whom 267 reported COPD at
baseline and an additional 19 indicated COPD at wave 2
(total 286) This follow-up and direct SHS monitoring par-
ticipation (see below) is summarized in Figure 1.
At wave 3, which was approximately 12 months after wave
2, we attempted to contact all 352 subjects with asthma or
COPD plus an additional 307 subjects who reported other
airways diseases reported at baseline (allergic rhinitis and
obstructive sleep apnea). Of the total 659 subjects, 433
completed the wave 3 interview (66%) and 229 subjects
had COPD, which included 27 newly reported COPD
cases at wave 3. Wave 4 was conducted about 12 months
after wave 3, with completion of interviews in 373 of 433
subjects (86%), which included 211 respondents with
COPD. There were no statistical differences in sociode-
mographcic characteristics (age, sex, race, educational
attainment), health status (COPD severity score or SF-12
physical component summary score), or smoking status
by follow-up status from wave 2 to wave 3 (p > 0.10 in all
cases). Subjects who completed wave 4 were more likely
to be white, non-hispanic (90% vs. 78%) and to have a
college or graduate degree (30 vs. 12%) than were those
who did not complete wave 4 follow-up (p < 0.05); there
were no other statistical differences (p > 0.10 in all cases).BMC Pulmonary Medicine 2006, 6:12 http://www.biomedcentral.com/1471-2466/6/12
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The current analysis was restricted to subjects who com-
pleted wave 3 and who reported no current smoking
(either wave 3 or wave 4, if applicable) and had urine coti-
nine levels that were less than 100 ng/ml, a level which is
consistent with direct personal smoking.[18-20] In sum,
152 current non-smoking subjects with COPD were eligi-
ble, of whom 77 subjects completed direct SHS monitor-
ing with urine cotinine and personal badge nicotine
measurements at baseline (wave 3), which corresponds to
a 51% completion rate. Of this group, 68 subjects com-
pleted the direct SHS exposure follow-up approximately 1
year later (wave 4) (88% completion rate among direct
SHS monitoring group). As shown in Table 1, there were
no statistical differences between the 152 current non-
smokers with COPD who did and did not complete base-
line direct SHS measurement (p > 0.15, all cases). There
were also no statistical differences between those who
completed baseline direct SHS assessment who did and
did not complete the 1 year follow-up assessment (p >
0.05, all cases).
Structured telephone interviews
Participants completed structured telephone interviews
that included health history, cigarette smoking, SHS expo-
sure, sociodemographic characteristics, and health status.
Direct personal cigarette smoking was evaluated using
standard questions from the National Health Interview
Survey. [21] Based on these responses, subjects were
defined as current smokers, ex-smokers, and never smok-
ers.
Details of sampling and recruitment for baseline through wave 4 Figure 1
Details of sampling and recruitment for baseline through wave 4. Wave 2 attempted to recruit all subjects who indicated a 
diagnosis of asthma or COPD at baseline. Wave 3 attempted to recruit all subjects followed in wave 2 plus those who indi-
cated a diagnosis of allergic rhinitis or obstructive sleep apnea at baseline. Wave 4 attempted to recruit subjects who com-
pleted wave 3 follow-up.
Followed in Wave 3 
433 (66% of 659) 
Followed in Wave 4 
373 (86%) 
With COPD 
211
With COPD 
202 W1/W2 
27 new in W3 
Total = 229
Baseline interview (wave 1) 
2,113
COPD or asthma diagnosis 
517
Followed in wave 2 
352 (68%) 
With COPD 
267 from W1 
19 new in W2 
Total = 286
Allergic rhinitis or sleep 
apnea
307
No airway condition 
1806
COPD & no current 
smoking = 152
Direct SHS monitoring = 77
COPD & no current 
smoking = 132
Direct SHS monitoring = 68BMC Pulmonary Medicine 2006, 6:12 http://www.biomedcentral.com/1471-2466/6/12
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Self-reported SHS exposure
We previously developed and validated a survey instru-
ment that assesses recent ETS exposure.[8] The instru-
ment, which was tailored for adults with asthma living in
Northern California, assesses exposure during the past 7
days in 6 microenvironments: the respondent's home,
another person's home, traveling in a car or another vehi-
cle, workplace (including dedicated smoking areas), bars
and nightclubs, and other locations. In each area, the
instrument ascertains the total duration (in hours) of
exposure during the past 7 days. Based on the distribution
of responses, we defined three categories of exposure: no
exposure, lower level exposure (1–3 hours/week), and
higher level (≥4 hours/week) exposure.
Direct SHS monitoring
We used a combined approach to conduct direct SHS
exposure monitoring based on urine cotinine and per-
sonal nicotine badges. Cotinine, a metabolite of nicotine,
is a widely used and specific biomarker of SHS expo-
sure.[22] Cotinine has a short half-life of 20 hours and
reflects shorter term SHS exposure than the personal nic-
otine badge that measures average 7-day exposures. Urine
samples and completed badges were returned to the inves-
tigators by mail (completion rates are provided above).
Concentrations of cotinine and trans-3'-hydroxycotinine,
which is the proximate metabolite of cotinine and the
most abundant metabolite of nicotine present in urine,
were determined using liquid chromatography-tandem
mass spectrometry (LC-MS/MS).[23,24] The method is
similar to a published method for determining cotinine
concentrations in serum of non-smokers.[25] Deuterium-
labeled cotinine (cotinine-d9) and deuterium-labeled
trans-3'-hydroxycotinine (trans-3'-hydroxycotinine-d9)
were used as internal standards. The mass spectrometer
was operated in the positive ion mode using atmospheric
pressure chemical ionization. Quantitation was achieved
using selected reaction monitoring (SRM) of the transi-
tions m/z 177 to m/z 80 for cotinine, m/z 193 to m/z 80
for trans-3'-hydroxycotinine and the transitions m/z 186
to m/z 84 and m/z 202 to m/z 84 for the respective inter-
nal standards. Limits of quantitation were 0.05 ng/mL for
cotinine and 0.1 ng/mL for trans-3'-hydroxycotinine.
The extent of hepatic metabolism of nicotine to cotinine,
which occurs primarily via cytochrome P450 2A6
(CYP2A6), and the rate of cotinine metabolism both
determine the mathematical relationship between nico-
tine intake from SHS exposure and cotinine level.[23]
There are substantial inter-individual differences in
CYP2A6 activity, which could affect cotinine levels for a
given nicotine dose. Because cotinine is also converted to
trans-3'-hydroxycotinine via CYP2A6, the ratio of trans-3'-
hydroxycotinine/cotinine is highly correlated with the
Table 1: Characteristics of adult non-smoking participants with COPD
Characteristic Overall non-smoking COPD 
cohort (n = 152)
Participants in direct SHS exposure assessment study
Completed initial assessment (n = 
77)
Completed baseline and 1 year 
follow-up assessment (n = 68)
Age (yrs) 64.4 (6.0) 65.0 (6.4) 64.8 (6.2)
Male gender (%) 55 (36%) 30 (39%) 27 (40%)
Race-ethnicity (white, non-
hispanic)
138 (91%) 72 (94%) 65 (96%)
Educational attainment
High school or less 75 (49%) 33 (43%) 31 (46%)
Some college 44 (29%) 26 (34%) 20 (29%)
College graduate or graduate 
degree
33 (22%) 18 (23%) 17 (25%)
Past smoking history (%) 109 (72%) 51 (66%) 45 (66%)
COPD severity score 8.2 (6.3) 8.3 (6.6) 8.2 (6.7)
SF-12 physical component 
summary score
35.0 (11.8) 34.8 (11.7) 35.4 (11.6)
Airways Questionnaire 20 (AQ-
20)
8.6 (5.0) 8.5 (4.7) 8.5 (4.6)
Modified MRC dyspnea score 2.5 (1.2) 2.5 (1.2) 2.5 (1.2)
Higher scores on COPD severity score, Airways Questionnaire 20, and modified MRC dyspnea score = poorer health status; higher score on SF-
12 Physical Component Summary Score = better health status. There were no statistical differences between non-smoking COPD participants who 
did and did not complete initial direct SHS assessment (p > 0.15, all cases) (data for those who did not complete initial direct SHS assessment are 
not shown separately); also no differences between those who completed initial direct SHS assessment who did and did not complete 1 yr follow-
up (p > 0.05, all cases).BMC Pulmonary Medicine 2006, 6:12 http://www.biomedcentral.com/1471-2466/6/12
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clearance of nicotine.[23] Consequently, this marker can
be used as a non-invasive marker of nicotine metabolism.
Each subject was instructed to wear the personal nicotine
badge monitor during regular activities for 7 days. The
passive monitor, which has been previously described,
samples nicotine from ambient air.[26,27] A 4-cm-diam-
eter polystyrene cassette holds a filter treated with sodium
bisulfate and a membrane filter functions as a windscreen.
Ambient nicotine diffuses to the treated filter, where it is
trapped. The collected nicotine is analyzed by gas chro-
motography with nitrogen selective detection. Based on
the amount of nicotine measured on the filter (ug), which
represents the total amount of nicotine collected during
the monitoring period, the nicotine concentrations were
calculated by dividing the nicotine collected by the esti-
mated volume of air sampled (monitoring duration mul-
tiplied by sampling rate of 24 ml/minute). The passive
monitors have a limit of detection less than 0.01 ug per fil-
ter and a coefficient of variability of 0.11 for replicate
analysis.[26] Based on the distribution of values, we
divided urine cotinine and badge nicotine levels into ter-
tiles for statistical analysis.
Study outcome variables: COPD-related health status
We used a combined approach with disease-specific and
generic health status measurements to assess COPD-
related health status. To measure disease severity, we pre-
viously developed and validated a disease-specific COPD
severity score for use in epidemiologic and outcomes
research.[28] Based on survey responses, the COPD sever-
ity score is comprised of 5 overall aspects of COPD sever-
ity: respiratory symptoms, systemic corticosteroid use,
other COPD medication use, previous hospitalization or
intubation for respiratory disease, and home oxygen use.
Each item was weighted based on clinical aspects of the
disease and its expected contribution to overall COPD
severity. Possible total scores range from 0 to 35, with
higher scores reflecting more severe COPD.
Generic physical health status was measured with the SF-
12 Physical Component Summary Score. The SF-12 is
derived from the Medical Outcomes Study SF-36 instru-
ment, which is the most widely used measure of generic
health status. The SF-36 has been extensively validated in
the general population[29] and among adults with
COPD.[30] Defined from the eight SF-36 subscales by fac-
tor analysis, the physical component summary score
reflects an underlying physical dimension of physical
HRQL.[31] Higher scores reflect more favorable health
states.
We used the Airways Questionnaire 20 (AQ-20) to meas-
ure disease specific quality of life.[32] This instrument is a
short survey that was validated against the St. George's
Respiratory Questionnaire, which is a 50 item instrument
that has been used extensively in COPD to measure dis-
ease-specific QOL.[33,34] It has excellent psychometric
properties for assessing QOL in COPD and asthma and
higher scores correspond to poorer QOL.[32,35] Dyspnea
was measured using three of five questions from the mod-
ified MRC dyspnea scale.[36] Higher scores indicate
greater levels of dyspnea.
Statistical analysis
Statistical analysis was conducted using SAS 9.1 (Cary,
NC). Bivariate analysis was conducted using the unpaired
t-test for continuous variables and likelihood ratio chi-
square test for dichotomous variables. The analysis was
conducted both for self-reported SHS exposure and
directly measured SHS exposure (urine cotinine and per-
sonal badge nicotine). To ensure comparable results, the
analysis was restricted to subjects who completed at least
baseline direct SHS monitoring. We used linear regression
analysis to examine the cross-sectional impact of SHS
exposure and health-related COPD status (COPD severity,
generic physical health status, disease-specific QOL, and
dyspnea). We used multivariate linear regression analysis
to control for variables that could confound the relation-
ship between SHS exposure and health outcomes, includ-
ing age, sex, race, educational attainment, and previous
smoking history (all subjects were current non-smok-
ers).[2,37] Furthermore, we used multivariate linear
regression to elucidate the impact of baseline SHS expo-
sure on COPD-related health status at 1 year follow-up.
To take into account inter-individual differences in nico-
tine metabolism, we repeated the multivariate analysis
after adding the ratio of trans-3'-hydroxycotinine/coti-
nine, a non-invasive measure of CYP2A6 activity, to the
model.
To express the "clinical significance" of the impact of SHS
on COPD-related health status, we expressed the change
in each health status variable in terms of proportional
change in standard deviation of the score. It has been
shown that a one-half standard deviation in health status
variables corresponds to the minimally important differ-
ence.[38] Consequently, we evaluated the impact of SHS
exposure on each health status variable according to this
criterion.
As above, participants in the direct SHS monitoring pro-
gram were similar to non-participants, including socioe-
conomic status, COPD severity, and physical health
status. To further take non-response into account, sam-
pling weights were developed using all the personal char-
acteristics in Table 1. The weighted analysis was not
substantively different from the unweighted analysis, so
we report the unweighted analysis only.BMC Pulmonary Medicine 2006, 6:12 http://www.biomedcentral.com/1471-2466/6/12
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Role of the funding source
The funding source was not involved in study design, data
collection, statistical analysis, or manuscript preparation.
Results
Subject characteristics
The majority of subjects were white and female, with an
average age of 64.4 years (Table 1). The cohort had a gen-
erally low educational attainment, with nearly half com-
pleting high school or less. Although all subjects were
current non-smokers (see Methods), the majority indi-
cated a previous history of smoking (72%). Baseline
health status indicators are also provided in the Table 1.
Self-reported SHS exposure and COPD-related health 
outcomes
Of the 77 non-smokers with COPD who completed direct
SHS monitoring, 26% (95% CI 17 to 37%) indicated 1 or
more hours of SHS exposure during the past 7 days. Table
2 shows the distribution of exposure for self-reported and
directly measured SHS exposure. The table also shows the
inter-relationship between the SHS measures (legend).
In cross-sectional analysis, self-reported lower level SHS
exposure (1–3 hours) was associated with poorer disease-
specific QOL (mean score increment 3.6 points; 95% CI
0.4 to 6.7 points) and dyspnea (mean score increment 1.1
points; 95% CI 0.3 to 1.8) after controlling for covariates
(Table 3). There was a suggestion that SHS exposure was
related to COPD severity and physical health status,
although the confidence intervals did not exclude the no
effect level (Table 3).
The prospective analysis revealed that lower level SHS
exposure (1–3 hours) was associated with poorer disease-
specific QOL (mean score increase 3.4 points; 95% CI 0.3
to 6.5 points) and MRC dyspnea score after controlling for
covariates (mean score increase 1.2 points; 95% CI 0.5 to
1.8 points) (Table 3). There was a suggestion that the self-
reported SHS exposure was related to greater COPD sever-
ity and poorer physical health status, but the estimates
were imprecisely estimated (Table 3).
Directly measured SHS exposure and COPD-related 
outcomes
The highest urine cotinine tertile was associated, in cross-
sectional multivariate analysis, with poorer COPD sever-
ity scores (mean score increment 4.7 points; 95% CI 0.6
to 8.9 points) and MRC dyspnea scores (score increment
1.0; 95% CI 0.4 to 1.7 points) (Table 4). There was a sug-
gestion that the highest cotinine levels were related to
greater impairment of physical health status scores (-5.6
points; 95% CI -12 to 1.0 points).
In longitudinal analysis, the highest urine cotinine tertile
was associated with greater dyspnea (mean score incre-
ment 0.9 points; 95% CI 0.2 to 1.6). The highest cotinine
level also appeared to be associated with worse COPD
severity (mean score increment 4.7 points; 95% CI -0.1 to
9.4 points; p = 0.054), physical health status (-5.7 points;
95% CI -14 to 2.0 points), and disease-specific QOL
Table 2: Distribution of SHS exposure among non-smokers with COPD by self-report and direct exposure monitoring
Measure N Proportion with any 
self-reported 
exposure or 
detectable urine/
badge level
SHS exposure among those with any exposure
25th %tile Median 75th %tile
Self-report, past 7 
days (hrs)
7 7 2 0  ( 2 6 % ) 127
Urine cotinine (ng/ml) 77 69 (90%) 0.092 0.20 0.81
First tertile* 26 14 (54%) 0 0.054 0.069
Second tertile 26 26 (100%) 0.12 0.16 0.22
Third tertile 25 25 (100%) 0.75 1.54 3.86
Personal nicotine 
badge (μg/m3)
77 64 (83%) 0.096 0.22 0.63
First tertile* 27 14 (52%) 0 0.023 0.061
Second tertile 24 24 (100%) 0.12 0.14 0.22
Third tertile 26 26 (100%) 0.45 0.86 1.53
*Based on the distribution, urine cotinine and personal badge nicotine levels were divided into tertiles for statistical analysis. Although lowest tertile 
contained some subjects with detectable values, these were very low values quantitatively.
Among 77 subjects with all three measures available, the Spearman rank correlation between self-reported SHS exposure and urine cotinine was 
0.28 (p = 0.013); between self-reported exposure and badge nicotine level was 0.06 (p = 0.57); between urine cotinine and badge nicotine was 0.41 
(p = 0.0002). When tertile of urine cotinine and nicotine badge were examined as categories, the Kappa was 0.33 (95% CI 0.16 to 0.50).BMC Pulmonary Medicine 2006, 6:12 http://www.biomedcentral.com/1471-2466/6/12
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(mean score increment 2.9 points (-0.16 to 5.9 points).
The confidence intervals, however, did not exclude not
effect. When compared to the standard deviation of each
score, these changes achieved the minimal important dif-
ference criterion of 0.5 standard deviations (sd) or greater
(i.e., COPD severity 0.7 sd, physical health status 0.5 sd,
disease-specific QOL 0.6 sd, and dyspnea score 0.8 sd).
Addition of trans-3'-hydroxycotinine/cotinine ratio to the
multivariate model had essentially no impact on the esti-
mates of SHS exposure effect (data not shown). The ratio
itself was not associated with any outcome variable (p >
0.70 in all cases).
In contrast, there was no statistical relation between nico-
tine badge levels and any study outcome in either cross-
sectional or prospective analysis (Tables 4 and 5).
Discussion
We report the first study to assess the impact of objectively
measured SHS exposure on a substantial cohort of adults
with COPD. Despite the fact that they have chronic respi-
ratory disease, SHS exposure was common among non-
smoking adults with COPD. Although the results varied
by measurement technique and type of analysis, SHS
exposure was generally associated with greater COPD
severity and poorer health status. The effect was observed
in both cross-sectional and prospective analysis and
appeared to be clinically meaningful, as judged against
the criterion of the minimally important difference in
health status indicators. Taking inter-individual differ-
ences in nicotine metabolism into account did not influ-
ence the estimates of SHS effect. These data suggest that
passive smoking, in addition to direct personal cigarette
smoking, may exert an important influence on outcomes
in COPD.
Although the literature is small, previous studies suggest
that SHS exposure may be a cause of new-onset COPD or
impaired pulmonary function.[2,39-41] The effect of SHS
exposure on persons with established COPD, however,
has received very little study.[5] In a cohort of adults hos-
pitalized for COPD, self-reported SHS exposure was a risk
factor for re-hospitalization.[6] In another study based on
the U.S. National Health Interview Survey, self-reported
ETS exposure was related to a greater risk of "chronic res-
piratory disease exacerbation," defined as activity limita-
tion or a physician visit due to asthma, chronic bronchitis,
emphysema, or chronic sinusitis. The present findings add
substantive additional evidence that SHS exposure is del-
eterious for patients with COPD.
The results differed somewhat depending on the method
used to measure SHS exposure. For self-reported exposure,
the overall pattern of results suggested a deleterious effect
of SHS exposure on COPD-related health status, but the
estimates were imprecise in many cases. This is probably
attributable to the lower accuracy of self-reported SHS
exposure. When urine cotinine was examined, which is an
objective and specific measure of SHS exposure, the asso-
ciation between higher SHS exposure and poorer COPD-
Table 3: Impact of self-reported SHS exposure (past 7 days) on COPD-related health status among 77 adults with COPD: cross-
sectional and prospective analysis
SHS 
exposure, 
past 7d
COPD 
severity
Physical 
health status 
(SF-12)
Disease-
specific QOL
Dyspnea
Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate
Cross-sectional analysis (n = 77)
None Referent Referent Referent Referent Referent Referent Referent Referent
1–3 hrs 1.0 (-3.2 to 
5.2)
1.7 (-2.7 to 
6.2)
-0.6 (-8.1 to 
6.9)
-5.9 (-12.8 to 
1.0)‡‡
2.4 (-0.7 to 
5.5)
3.6 (0.4 to 
6.7)
0.5 (-0.3 to 
1.2)
1.1 (0.3 to 
1.8)
≥4 hrs 4.1 (-0.91 to 
9.0)†
3.8 (-1.2 to 
8.8)
-1.5 (-10.4 to 
7.4)
-1.3 (-9.1 to 
6.6)
1.0 (-2.8 to 
4.8)
1.2 (-2.4 to 
4.7)
0.2 (-0.7 to 
1.1)
0.2 (-0.6 to 
1.0)
Impact of baseline SHS exposure on prospective outcomes at 1 year (n = 68)
None Referent Referent Referent Referent Referent Referent Referent Referent
1–3 hrs 3.2 (-1.2 to 
7.7)
3.6 (-1.1 to 
8.2)
-5.7 (-13.2 to 
1.8)
-7.2 (-14.9 to 
0.5) ‡
2.5 (-0.9 to 
5.8)
3.4 (0.3 to 
6.5)
0.9 (0.2 to 
1.7)
1.2 (0.5 to 
1.8)
≥4 hrs 4.9 (-0.2 to 
9.9)*
4.1 (-1.1 to 
9.2)††
-6.5 (-15.0 to 
2.1)
-4.9 (-13.5 to 
3.7)
2.6 (-1.2 to 
6.4)
1.6 (-1.8 to 
5.1)
0.4 (-0.4 to 
1.3)
0.2 (-0.5 to 
1.0)
Values are mean score change compared to lowest exposure tertile (referent group) and 95% confidence interval. The lower and higher SHS 
exposure groups were defined based on the median among those with any exposure. Multivariate analysis controls for age, sex, race, educational 
attainment, and past smoking history. Physical health status was measured by the SF-12 physical component summary score; Disease-specific QOL 
was measured by the Airways Questionnaire 20 (AQ-20); Dyspnea was measured by the modified MRC Dyspnea Scale. Higher scores = worse 
status, except for SF-12 physical score. There were 57 subjects, 12 subjects, and 8 subjects in the none, 1–3 hrs, and ≥4 hrs/week exposure groups, 
respectively.
Boldface = p < 0.05.
*p = 0.06 ‡P = 0.07 ‡‡p = 0.09 †p = 0.11 ††p = 0.12BMC Pulmonary Medicine 2006, 6:12 http://www.biomedcentral.com/1471-2466/6/12
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related health status was most clearly demonstrated. Per-
sonal badge nicotine levels, in contrast, were not associ-
ated with any health status variable. The different results
for urine cotinine and personal badge nicotine levels may
indicate that peak SHS exposure, rather than average SHS
exposure, is more relevant to disease severity and health
status in COPD. Personal badge data represent an inte-
grated average exposure to nicotine during the time
period that the badge is worn, whereas urinary cotinine
data are more reflective of recent peak exposures. Alterna-
tively, the personal nicotine badge measurements may
have been subject to greater exposure misclassification
than urine cotinine, because correct measurement
depended on subjects reliably wearing the badge during
Table 5: Prospective impact of directly measured SHS exposure on COPD-related health status at 1 year follow-up (n = 68)
SHS exposure COPD 
severity
Physical 
health status 
(SF-12)
Disease-
specific QOL
Dyspnea
Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate
Urine 
cotinine
1st tertile Referent Referent Referent Referent Referent Referent Referent Referent
2nd tertile 2.8 (-1.2 to 
6.7)
1.9 (-2.3 to 
6.0)
0.4 (-6.3 to 
7.0)
2.6 (-4.2 to 
9.4)
-0.3 (-3.1 to 
2.5)
-1.4 (-4.1 to 
1.3)
0.1 (-0.8 to 
0.6)
-0.2 (-0.8 to 
0.4)
3rd tertile 5.8 (1.5 to 
10.2)
4.7 (-0.1 to 
9.4)*
-7.8 (-15 to -
0.6)
-5.7 (-14 to 
2.0)
4.5 (1.3 to 
7.6)
2.9 (-0.16 to 
5.9)†
1.2 (0.5 to 
1.9)
0.9 (0.2 to 
1.6)
Nicotine 
badge
1st tertile Referent Referent Referent Referent Referent Referent Referent Referent
2nd tertile 0.5 (-3.6 to 
4.6)
1.0 (-3.3 to 
5.3)
0.1 (-6.8 to 
6.9)
-0.2 (-7.2 to 
6.9)
-0.2 (-3.1 to 
2.8)
0.3 (-2.5 to 
3.0)
-0.1 (-0.8 to 
0.6)
0 (-0.7 to 0.6)
3rd tertile -0.7 (-4.8 to 
3.5)
-0.3 (-4.6 to 
4.0)
-1.1 (-8.1 to 
5.9)
-2.1 (-9.2 to 
5.0)
-0.1 9–3.1 to 
2.9)
0.9 (-1.9 to 
3.7)
0 (-0.6 to 0.7) 0.2 (-0.5 to 
0.8)
All values are mean score change compared to lowest exposure tertile (referent group) and 95% confidence interval. Multivariate analysis controls 
for age, sex, race, educational attainment, and past smoking history. Physical health status was measured by the SF-12 physical component summary 
score; Disease-specific QOL was measured by the Airways Questionnaire 20 (AQ-20); Dyspnea was measured by the modified MRC Dyspnea 
Scale. Higher scores = worse status, except for SF-12 physical score.
Boldface = p < 0.05.
*p = 0.054
†p = 0.063
Table 4: Cross-sectional association between directly measured SHS exposure and COPD-related health status (n = 77).
SHS exposure COPD 
severity
Physical 
health status 
(SF-12)
Disease-
specific QOL
Dyspnea
Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate
Urine 
cotinine
1st tertile Referent Referent Referent Referent Referent Referent Referent Referent
2nd tertile 1.2 (-2.5 to 
4.8)
0.2 (-3.6 to 
3.9)
-2.3 (-8.9 to 
4.2)
0.4 (-5.6 to 
6.5)
-0.4 (-3.2 to 
2.4)
-0.7 (-3.5 to 
2.0)
-0.1 (-0.7 to 
0.6)
-0.3 (-0.9 to 
0.3)
3rd tertile 5.4 (1.4 to 
9.3)
4.7 (0.6 to 
8.9)
-7.8 (-14.9 
to -0.7)
-5.6 (-12 to 
1.0)
2.9 (-0.16 to 
6.0)
2.3 (-0.7 to 
5.4)
1.1 (0.5 to 
1.8)
1.0 (0.4 to 
1.7)
Nicotine 
badge
1st tertile Referent Referent Referent Referent Referent Referent Referent Referent
2nd tertile 0.2 (-3.6 to 
3.9)
0.6 (-3.2 to 
4.4)
3.0 (-3.7 to 
9.8)
2.7 (-3.4 to 
8.8)
-1.6 (-4.5 to 
1.4)
-1.7 (-4.6 to 
1.2)
-0.2 (-0.8 to 
0.5)
-0.2 (-0.8 to 
0.4)
3rd tertile -1.4 (-5.3 to 
2.5)
-1.1 (-5.0 to 
2.8)
3.2 (-3.8 to 
10.1)
1.9 (-4.3 to 
8.2)
-2.1 (-5.1 to 
0.9)
-1.6 (-4.5 to 
1.3)
-0.2 (-0.9 to 
0.5)
-0.1 (-0.7 to 
0.5)
All values are mean score change compared to lowest exposure tertile (referent group) and 95% confidence interval. Multivariate analysis controls 
for age, sex, race, educational attainment, and past smoking history. Physical health status was measured by the SF-12 physical component summary 
score; Disease-specific QOL was measured by the Airways Questionnaire 20 (AQ-20); Dyspnea was measured by the modified MRC Dyspnea 
Scale. Higher scores = worse status, except for SF-12 physical score. Boldface = p < 0.05.BMC Pulmonary Medicine 2006, 6:12 http://www.biomedcentral.com/1471-2466/6/12
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all their daily activities (whereas urine cotinine was not).
These methodologic differences likely also account for the
low correlation among measures.
We used the standard epidemiologic definition of COPD,
based on a self-reported physician diagnosis of chronic
bronchitis, emphysema, or COPD [12-14]. This survey-
based approach, supplemented by a mail-based sample
acquisition strategy, allowed us to study a population-
based sample of adults who resided throughout the
United States, enhancing the generalizability of our find-
ings. On logistical grounds, conducting spirometry
among subjects who reside thousands of miles apart
would be highly difficult, if not impossible. The use of
self-reported physician-diagnosis, however, may have
resulted in some misclassification of disease status. Previ-
ous work indicated that a similar survey-based definition
of COPD had a high positive predictive value (78%) when
validated using a blinded medical record review that
included spirometry and radiographic studies. [42] Other
work confirmed that a self-reported history of COPD is a
strong predictor of airflow obstruction [43]. Our previous
validation study indicated that nearly 9 out of 10 partici-
pants who had available spirometry data had objective
evidence of airflow obstruction.[2] In sum, misclassifica-
tion of COPD is not likely to bias our results; if present,
such bias would likely be non-differential with respect to
SHS exposure and reduce effect estimates towards the null
value.
Although direct SHS exposure measurement is a more
accurate method than self-report, it is more labor inten-
sive and required a greater degree of commitment from
study subjects. Reflecting these facts, not all eligible sub-
jects participated in direct monitoring, which could have
introduced selection bias. However, the similarity of par-
ticipants and non-participants reduced the likelihood of
this potential bias. In addition, incorporating sample
weights that account for non-response into the analysis
had a negligible impact on study results (data not shown).
The other consequence of lower study participation is
diminished statistical power, which resulted in decreased
precision of effect estimates. In some cases, there
appeared to be a negative effect of SHS exposure, but the
95% confidence intervals were wide and included no
association. A larger sample size might have resulted in
clearer evidence of SHS effects in these cases and would be
required to detect smaller effects
Other limitations include the potential confounding
effects of direct cigarette smoking. We attempted to reduce
this confounding effect by limiting the analysis to persons
who indicated no current smoking and had urine cotinine
levels below a cut-point usually associated with active
smoking. We also statistically controlled for a past history
of cigarette smoking in multivariate analysis. Nonethe-
less, we cannot fully exclude confounding by active smok-
ing. And finally, although direct SHS exposure
measurement eliminated the bias inherent in self-
reported exposure, a bias termed the "healthy passive
smoker effect" can still occur, meaning that more severely
affected COPD patients may selectively avoid SHS expo-
sure, attenuating the observed association between expo-
sure and asthma health outcomes.
Conclusion
There is no question that cigarette smoking is the domi-
nant risk factor for COPD and is the most important fac-
tor driving the progression of airflow obstruction. Our
results implicate SHS exposure as another important fac-
tor influencing disease severity and health status in this
health condition. Because SHS is a modifiable risk factor,
clinicians should assess SHS exposure in their patients
and counsel its avoidance. In public health terms, the
effects of SHS exposure on this vulnerable subpopulation
provide a further rationale for laws prohibiting public
smoking.
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